MedTrace Logo

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

NCT04184518 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-06-02

No results posted yet for this study

Summary

Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.

Conditions

Interventions

DRUG

Cediranib Maleate

Cediranib 20mg, oral, 5 days on and 2 days off until disease progression

DRUG

Durvalumab

Durvalumab 1500mg, intravenous, every 4 weeks until disease progression

Sponsors & Collaborators

  • MFAR

    collaborator OTHER

  • Grupo Español Multidisciplinar de Melanoma

    lead OTHER

Principal Investigators

  • José M. Piulats · Institut Català d'Oncología L'Hospitalet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184518 on ClinicalTrials.gov